ArticlePhysiological research2025
miR-126-3p Protects Neonatal Rats With Hypoxic-Ischemic Brain Damage Through Targeting LPR6 via PKC/ERK Signaling Pathway.
Article in Physiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identifying pyroptosis-hub genes and immune infiltration in neonatal hypoxic-ischemic brain injury.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal hypoxic-ischemic brain damage (HIBD) is a common factor in neonatal fatalities. miR-126-3p content in cerebral hemorrhage patients is obviously decreased, but its mechanism of action in HIBD is still unclear. The HIBD model was constructed by Rice-Vannucci method, and the change in miR-126-3p was detected. The target genes of miR-126-3p were obtained by database (miRWalk, TargetScan, miRTarbase and miRDB) analysis. The targeting relationship between miR-126-3p and low density lipoprotein receptor related protein (LRP6) was explored based on a dual luciferase assay. miR-126-3p over- and lowexpressed, LRP6 overexpressed and protein kinase C (PKC) pathway agonist phorbol 12-myristate 13-acetate (PMA) were injected into the brains of neonatal rats. The pathological changes in cerebral tissue and neuronal survival were observed by pathological staining. The neurological function was evaluated by foot fault test and wire suspension test. The levels of interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha (TNF-alpha) were tested by an ELISA kit. The levels of miR-126-3p, LRP6 and PKC/ERK pathway proteins were tested by qRT-PCR and Western blot. Knockdown of miR-126-3p can aggravate inflammation, brain tissue pathology and neurological impairment in HIBD, while miR-126-3p overexpression can improve it. miR-126-3p can target down-regulate LRP6. miR-126-3p can improve HIBD by down-regulating LRP6 expression and activating the PKC/ERK signaling pathway. miR-126-3p can target down-regulate LRP6 by activating the PKC/ERK signaling pathway to inhibit inflammation in HIBD rats, reduce brain tissue pathology and neurological damage, and improve HIBD. Key words miR-126-3p " LPR6 " PKC/ERK pathway " Hypoxic-ischemic brain damage.
Indexed as
Identifiers
40709490PMC12462712What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.